News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-11-13 pm EST			5-day change	1st Jan Change
9.370 ^USD	+0.64%		-11.35%	-40.24%

Nov. 09	Monte Rosa Therapeutics Presents Preclinical Data On MRT-8102 In Gout	CI
Nov. 05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI

All News

Mentions Relevance

8c37b1f623d6e116f954af40661.esZdeIAgKIVuhPPaqv95KxV6cOVfYyBjCsaH_bIvRCg.ALVkH9daW90I3oOz-ao0elYQNqM2VkZSZZ_RiN1HdUct6xAXx1ZmtQ-0ww

Nov. 09	Monte Rosa Therapeutics Presents Preclinical Data On MRT-8102 In Gout	CI
Nov. 09	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout	GL
Nov. 05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
Nov. 05	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q3 Collaboration Revenue $54.4M, vs. FactSet Est of $33.9M	MT
Nov. 05	Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates	GL
Nov. 03	Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Nov. 02	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
Oct. 28	Monte Rosa Therapeutics Announces Second Phase 2 Clinical Study Initiation for VAV1-Directed Molecular Glue Degrader MRT-6160	CI
Oct. 28	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
Oct. 12	UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating	MT
Oct. 02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Oct. 01	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI
Oct. 01	Monte Rosa Therapeutics, Inc. - Special Call
Oct. 01	Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study	MT
Oct. 01	Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk	GL
Oct. 01	HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target	MT
Sep. 30	Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk	GL
Sep. 08	Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160	CI
Sep. 08	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
Sep. 02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Sep. 01	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
Aug. 24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
Aug. 24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI
Aug. 24	Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	GL
Aug. 06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI